Current Therapy and Challenges for Neurodegenerative Diseases
DOI:
https://doi.org/10.62051/4jzkgx69Keywords:
Neurodegenerative diseases; therapy; challenges.Abstract
Neurodegenerative diseases are a group of diseases characterized by progressive loss and dysfunction of neurons, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, among others. Neurodegenerative diseases can be studied using epidemiology, which is the science of studying the distribution, effects and determinants of diseases, health conditions and events in a population, as well as countermeasures and measures for the prevention and control of diseases and the promotion of health. The incidence rate of a disease can be obtained by epidemiological studies, which is an indicator of the number of new cases in a population. This indicator is similar to the incidence rate and indicates the severity of the epidemic over a relatively short period of time. The incidence of neurodegenerative diseases increases with age, placing a huge burden on patients and their families. In recent years, with the deepening of research into the mechanisms of neurodegenerative diseases, scientists have gradually revealed the complex biological processes behind these diseases and developed a number of potential treatment strategies. This article will provide an overview of the current state of neurodegenerative disease research, recent advances, therapeutic method, and future challenges.
Downloads
References
[1] Song Weining, et al. Angelicae Sinensis Radix in Neurodegenerative Diseases [J]. Chinese Journal of Experimental Traditional Medical Formulae, 2024 (30): 279-287, 2024.
[2] Islam, F., et al. Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer's disease from bench to bedside [J]. Molecular Neurobiology, 2022: 1-18.
[3] Sun, L., et al. Ectodermal mesenchymal stem cells: a promising candidate for stem cell therapy in neurodegenerative diseases [J]. Stem Cell Research & Therapy, 2021: 1-17.
[4] Chao Xiang, et al. The Frontier Progress of Emerging Therapies of CAR-T Cell Therapy [J]. Chinese Medical Guide Journal, 2022: 974-982.
[5] Zheng Nannan, et al. recent Advances in CAR-T Cell Immunotherapy. Pharmaceutical Biotechnology [J], 2019 (3): 273-277.
[6] Diao Yun, et al. Research progress on the application of CRISPR/Cas system in virus detection [J]. Chinese Journal of Virology, 2023 (6): 1694-1702, 2023.
[7] Frisoni, G. B., et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised [J]. Nature Reviews Neurology, 2022: 1-13.
[8] Van de Haar HJ, et al. Blood-brain barrier leakage in patients with early Alzheimer disease [J]. Radiology, 2017 (2): 615.
[9] Leuchtenburg, K. et al. Chimeric Antigen Receptor T cells Targeting B-amyloid in a Mouse Model of Alzheimer's Disease [J]. Nature Medicine, 2022 (3), 550-558.
[10] Lee, J. H., et al. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques [J]. Nature Neuroscience, 2022 (6): 863-876.
[11] Chen Qiting, et al. Research progress on the pathophysiology and neural mechanisms of freezing of gait in Parkinson's disease [J]. Hainan Med J, 2024 (5): 747-751.
[12] Wang, Y. et al. CAR-T cells for the treatment of Parkinson's disease: current status and future perspectives. Journal of Neurology [J]. Neurosurgery & Psychiatry, 2023 (1): 101-109.
[13] Cai Qiong, et al. Research progress in gene therapy for Parkinson's disease [J]. Chinese Journal of Neuropsychiatric Diseases, 2015 (41): 701-704.
[14] Liu Zhihua. Effect and mechanism of LRRK2 gene regulated cell transplantation based on CRISPR/CAS9 technology on rat model of Parkinson's disease [J]. Master's thesis of South China University of Technology, 2022.
Downloads
Published
Conference Proceedings Volume
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







